One-time Gene Therapy for Sickle Cell Disease

Aruvant is developing ARU-1801, a one-time, potentially curative gene therapy for sickle cell disease andβ-thalassemia. In an ongoing clinical phase 1/2 study, ARU-1801, administered with only reduced intensity conditioning,has provided stable reductions in disease...